High tumour cannabinoid cb receptor immunoreactivity negatively impacts disease-specific survival in stage ii microsatellite stable colorectal cancer

HIGHLIGHTS

• who: Cancer et al. from the Department of Pharmacology and Clinical Neuroscience, Pharmacology, Department of Medical Biosciences, PathologyPalmqvist have published the paper: High Tumour Cannabinoid CB Receptor Immunoreactivity Negatively Impacts Disease-Specific Survival in Stage II Microsatellite Stable Colorectal Cancer, in the Journal: (JOURNAL) of August/25,/2011
• what: The authors have investigated whether CB1 receptor immunoreactive intensity (CB1IR intensity) is associated with disease severity and outcome. The formalin-fixed, paraffin-embedded samples used in this study were obtained from tissue collected during primary tumour surgical resection of colorectal cancer (CRUMS (Colorectal cancer in Umeau030a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.